Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Antonio Piga, Silverio Perrotta, Maria Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Aldo Filosa, Vincenzo Caruso, Antonello Pietrangelo, Filomena Longo, Immacolata Tartaglione, Caterina Borgna-Pignatti, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie

Blood (2019) 133 (12): 1279–1289.

https://doi.org/10.1182/blood-2018-10-879247

Published: 2019

Includes: Supplemental data

Journal Articles

Is the Time of Revisiting Classification of Thalassemia Syndromes According with the Phenotype Severity?

Angela Vitrano, PhD, Giuseppina Calvaruso, MD, Lorella Pitrolo, MD, Alessia Pepe, MD, Antonella Meloni, PhD, Laura Pistoia, MD, Maria Rita Gamberini, MD, Vincenzo Caruso, MD, Aldo Filosa, MD, Paolo Ricchi, MD, Liana Cuccia, MD, Domenico D'Ascola, MD, Francesco Sorrentino, MD, Angelo Peluso, MD, Aurelio Maggio, MD

Blood (2017) 130 (Supplement 1): 935.

https://doi.org/10.1182/blood.V130.Suppl_1.935.935

Published: 2017

Journal Articles

A MRI Prospective Survey on Heart and Liver Iron and Cardiac Function in Thalassemia Major Patients Treated with Deferasirox Versus Deferiprone and Desferrioxamine in Monotherapy

Alessia Pepe, Laura Pistoia, Liana Cuccia, Monica Fortini, Vincenzo Caruso, MD, Rosamaria Rosso, Saveria Campisi, Angelo Peluso, Francesco Sorrentino, Aurelio Maggio, MD, Vincenzo Positano, Giuseppe Peritore, Antonella Meloni

Blood (2016) 128 (22): 3631.

https://doi.org/10.1182/blood.V128.22.3631.3631

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Antonio G. Piga, MD, Immacolata Tartaglione, MD, Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, MD, Paolo Ricchi, MD, Vincenzo Caruso, MD, Antonello Pietrangelo, MD, Xiaosha Zhang, Dawn M. Wilson, Ashley Leneus, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2016) 128 (22): 851.

https://doi.org/10.1182/blood.V128.22.851.851

Published: 2016

Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 752.

https://doi.org/10.1182/blood.V126.23.752.752

Published: 2015

Journal Articles

Survival Comparability Between Thalassemia Major Versus Thalassemia Intermedia

Blood (2015) 126 (23): 2141.

https://doi.org/10.1182/blood.V126.23.2141.2141

Published: 2015

Journal Articles

Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies

Blood (2015) 126 (23): 2146.

https://doi.org/10.1182/blood.V126.23.2146.2146

Published: 2015

Journal Articles

Randomized, Open Label, Phase IIa Controlled Trials Evaluating the Safety of the Association of Deferasirox with Standard Antiviral Therapy (Peg-interferon and Ribavirin) in Patients with Chronic Hepatitis C

Francesca Pileri, MD, Alberto Vegetti, MD, Luca De Pietri, MD, Gianluca Abbati, MD, Paolo Ventura, MD, Maria Rita Gamberini, MD, Vincenzo Caruso, Francesca Ferrara, Antonello Pietrangelo, MD, PhD

Blood (2014) 124 (21): 4075.

https://doi.org/10.1182/blood.V124.21.4075.4075

Published: 2014

Journal Articles

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

Antonio G. Piga, MD, Silverio Perrotta, MD, Angela Melpignano, MD, Caterina Borgna-Pignatti, MD, Ersi Voskaridou, MD, Vincenzo Caruso, MD, Aldo Filosa, MD, Yesim Aydinok, MD, Carrie Condon, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 53.

https://doi.org/10.1182/blood.V124.21.53.53

Published: 2014

Journal Articles

The Prognostic Role of Diabetes Mellitus for Cardiac Complications in a Large Cohort of Well Treated Thalassemia Major Patients

Antonella Meloni, PhD, Maria Rita Gamberini, MD, Giuseppe Rossi, MSc, Francesco Sorrentino, MD, Domenico Giuseppe D'Ascola, MD, Anna Spasiano, MD, Aldo Filosa, MD, Liana Cuccia, MD, Nicola Dello Iacono, MD, Gianluca Forni, MD, Vincenzo Caruso, MD, Aurelio Maggio, MD, Lorella Pitrolo, MD, Angelo Peluso, MD, Massimo Midiri, MD, Massimiliano Missere, MD, Maria Giovanna Neri, PhD, Alessia Pepe, MD PhD

Blood (2014) 124 (21): 4043.

https://doi.org/10.1182/blood.V124.21.4043.4043

Published: 2014

Journal Articles

Central Role of LIC-R2 (Ferriscan®) Determination in Patients with Hemoglobinopathies: Licnet Experience

Blood (2014) 124 (21): 4034.

https://doi.org/10.1182/blood.V124.21.4034.4034

Published: 2014

Journal Articles

Assessment and Management of Iron Overload in β-Thalassemia Major Patients in Italy: A Real-Life Experience From the Webthal® Project

Antonio Piga, MD, Filomena Longo, Khaled M Musallam, Maria Domenica Cappellini, MD, Gian Luca Forni, MD, Giovanni Quarta, Francesco Chiavilli, Francesca Valeria Commendatore, Sergio Mulas, Vincenzo Caruso, Renzo Galanello, MD

Blood (2012) 120 (21): 1030.

https://doi.org/10.1182/blood.V120.21.1030.1030

Published: 2012

Journal Articles

Repeated Echocardiographic Left Ventricular Ejection Fraction Measurements: A Strong and Accessible Tool for Detecting At High Risk of Heart Failure Thalassemia Major Population,

Blood (2011) 118 (21): 3197.

https://doi.org/10.1182/blood.V118.21.3197.3197

Published: 2011

Journal Articles

Prospective Comparison on Cardiac and Hepatic Iron and Cardiac Function by MR in Thalassemia Major Patients Treated with Combination Deferiprone–Desferrioxamine Versus Deferiprone and Desferrioxamine in Monoterapy,

Alessia Pepe, Antonella Meloni, PhD, Pasquale Pepe, Marcello Capra, M.D., Domenico Giuseppe D'Ascola, Michele Santodirocco, Paolo Cianciulli, M.D., Vincenzo Caruso, M.D., Maria Antonietta Romeo, M.D., Aldo Filosa, Lorella Pitrolo, Maria Caterina Putti, MD, Aurelio Maggio, MD, Massimiliano Missere, Vincenzo Positano, Massimo Lombardi, Paolo Ricchi

Blood (2011) 118 (21): 3194.

https://doi.org/10.1182/blood.V118.21.3194.3194

Published: 2011

Journal Articles

Diabetes Mellitus and Cardiac Complications in Thalassemia Major Patients

Maria Rita Gamberini, Antonella Meloni, PhD, Vincenzo Caruso, M.D., Marcello Capra, M.D., Paolo Cianciulli, M.D., Aurelio Maggio, MD, Elisabetta Chiodi, Massimo Lombardi, Alessia Pepe

Blood (2011) 118 (21): 2150.

https://doi.org/10.1182/blood.V118.21.2150.2150

Published: 2011

Journal Articles

Different Patterns of Myocardial Iron Overload by T2* Cardiovascular MR As Markers of Risk for Cardiac Complication in Thalassemia Major,

Antonella Meloni, PhD, Pasquale Pepe, Petra Keilberg, Brunella Favilli, Vincenzo Positano, Marcello Capra, Vincenzo Caruso, M.D., Paolo Cianciulli, Aldo Filosa, Angelo Zuccarelli, Lucia De Franceschi, MD, Massimo Lombardi, Alessia Pepe

Blood (2011) 118 (21): 3190.

https://doi.org/10.1182/blood.V118.21.3190.3190

Published: 2011

Journal Articles

Prospective Survey on Heart and Liver Iron and Heart Function in Thalassemia Major Patients Treated with Sequential deferiprone–desferrioxamine Versus Deferiprone and Desferrioxamine in Monotherapy

Alessia Pepe, Antonella Meloni, PhD, Giuseppe Rossi, Anna Spasiano, Domenico Giuseppe D'Ascola, Aldo Filosa, Vincenzo Caruso, M.D., Paolo Cianciulli, M.D., Maria Antonietta Romeo, M.D., Maria Caterina Putti, MD, Angelo Peluso, Maria Grazia Bisconte, Maria Eliana Lai, Aurelio Maggio, MD, Cristina Salvatori, Massimo Lombardi, Marcello Capra, M.D.

Blood (2011) 118 (21): 5298.

https://doi.org/10.1182/blood.V118.21.5298.5298

Published: 2011

Journal Articles

Long-Term Use of Deferiprone Enhances Significantly the Left Ventricular Ejection Function in Thalassemia Major

Blood (2011) 118 (21): 5302.

https://doi.org/10.1182/blood.V118.21.5302.5302

Published: 2011

Journal Articles

A T2* MRI Prospective Survey on Heart and Liver Iron In Thalassemia Major Patients Treated with Deferasirox Versus Deferiprone and Desferrioxamine In Monotherapy

Alessia Pepe, PhD, Giuseppe Rossi, PhD, Antonella Meloni, PhD, Maria Chiara Dell'Amico, Anna Spasiano, PhD, Marcello Capra, PhD, Paolo Cianciulli, PhD, Vincenzo Caruso, PhD, Brunella Favilli, PhD, Eliana Cracolici, PhD, Massimo Lombardi, PhD, Aurelio Maggio

Blood (2010) 116 (21): 4267.

https://doi.org/10.1182/blood.V116.21.4267.4267

Published: 2010

Journal Articles

Magnetic Resonance T2* Technique for Segmental and Global Quantification of Myocardial Iron : Multi-Centre Validation in the MIOT (Myocardial Iron Overload in Thalassemia) Network

Vincenzo Positano, MSc, Anna Ramazzotti, PhD, Alessia Pepe, MD, PhD, Cristina Salvatori, MSc, Paolo Marcheschi, MSc, Antonella Meloni, MSc, Maurizio Mangione, MSc, Maria Filomena Santarelli, PhD, Paolo Cianciulli, MD, Vincenzo Caruso, MD, Aurelio Maggio, MD, Luigi Landini, PhD, Massimo Lombardi, MD

Blood (2008) 112 (11): 5420.

https://doi.org/10.1182/blood.V112.11.5420.5420

Published: 2008

NARROW

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Is the Time of Revisiting Classification of Thalassemia Syndromes According with the Phenotype Severity?

A MRI Prospective Survey on Heart and Liver Iron and Cardiac Function in Thalassemia Major Patients Treated with Deferasirox Versus Deferiprone and Desferrioxamine in Monotherapy

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Survival Comparability Between Thalassemia Major Versus Thalassemia Intermedia

Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies

Randomized, Open Label, Phase IIa Controlled Trials Evaluating the Safety of the Association of Deferasirox with Standard Antiviral Therapy (Peg-interferon and Ribavirin) in Patients with Chronic Hepatitis C

ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study

The Prognostic Role of Diabetes Mellitus for Cardiac Complications in a Large Cohort of Well Treated Thalassemia Major Patients

Central Role of LIC-R2 (Ferriscan®) Determination in Patients with Hemoglobinopathies: Licnet Experience

Assessment and Management of Iron Overload in β-Thalassemia Major Patients in Italy: A Real-Life Experience From the Webthal® Project

Repeated Echocardiographic Left Ventricular Ejection Fraction Measurements: A Strong and Accessible Tool for Detecting At High Risk of Heart Failure Thalassemia Major Population,

Prospective Comparison on Cardiac and Hepatic Iron and Cardiac Function by MR in Thalassemia Major Patients Treated with Combination Deferiprone–Desferrioxamine Versus Deferiprone and Desferrioxamine in Monoterapy,

Diabetes Mellitus and Cardiac Complications in Thalassemia Major Patients

Different Patterns of Myocardial Iron Overload by T2* Cardiovascular MR As Markers of Risk for Cardiac Complication in Thalassemia Major,

Prospective Survey on Heart and Liver Iron and Heart Function in Thalassemia Major Patients Treated with Sequential deferiprone–desferrioxamine Versus Deferiprone and Desferrioxamine in Monotherapy

Long-Term Use of Deferiprone Enhances Significantly the Left Ventricular Ejection Function in Thalassemia Major

A T2* MRI Prospective Survey on Heart and Liver Iron In Thalassemia Major Patients Treated with Deferasirox Versus Deferiprone and Desferrioxamine In Monotherapy

Magnetic Resonance T2* Technique for Segmental and Global Quantification of Myocardial Iron : Multi-Centre Validation in the MIOT (Myocardial Iron Overload in Thalassemia) Network

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only